Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an announcement.
Chimeric Therapeutics Ltd. has announced the quotation of a new class of options on the Australian Securities Exchange (ASX), with 624,999,999 options expiring on December 19, 2025, at an exercise price of $0.008. This move is expected to enhance the company’s capital structure, potentially providing additional funding for its ongoing research and development efforts in the field of cancer immunotherapy, thereby strengthening its position in the biotechnology sector.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is primarily engaged in creating and advancing chimeric antigen receptor T cell (CAR-T) therapies to address unmet medical needs in oncology.
Technical Sentiment Signal: Buy
Current Market Cap: A$11.34M
See more data about CHM stock on TipRanks’ Stock Analysis page.